PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds
Tel Aviv, Israel – December 26, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 467,896 ordinary shares, having […]
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trialto Evaluate PRF-110 in Patients Undergoing Bunionectomy SurgeryFollowing Positive FDA Review of Drug Master File
Targeting to commence second part of Phase 3 clinical trial in mid-Q4 2023 Trial completion and results expected in mid-2024 Tel Aviv, Israel – September 11, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced plans to commence the second […]
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary
Professor Eli Hazum to Share Positive Safety and PK Data of PRF-110 from First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Tel Aviv, Israel – September 7, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, […]
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City
Tel Aviv, Israel – September 5, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will be attending the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at […]
PainReform Provides Business Update for the Second Quarter of 2023
Targeting to commence second part of Phase 3 clinical trialin bunionectomy during the fourth quarter of 2023 Tel Aviv, Israel – August 10, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the second quarter ended […]
PainReformAnnounces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement
Tel Aviv, Israel – July 12, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for the purchase and sale of 301,230 of the Company’s ordinary shares (or pre-funded warrants in lieu […]
PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
Tel Aviv, Israel – June 7, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a regulatory update on the second part of its Phase 3 clinical trial of PRF-110 in patients undergoing bunionectomy surgery. The Company’s supplier of the […]
PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery
Reports excellent compliance with FDA safety requirements in the first partof its Phase III with 15 patients Tel Aviv, Israel – May 18, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive pharmacokinetic (PK) data in the first part […]
PainReform Provides Business Update for the First Quarter of 2023
Reports Progress on Phase 3 Clinical Trial of PRF-110in Patients Undergoing Bunionectomy Surgery Tel Aviv, Israel – May 15, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2023. Ilan […]
PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trialof PRF-110 in Patients Undergoing Bunionectomy Surgery
Reports Solid Safety Profile of PRF-110 andNo Serious Adverse Events among First 15 Patients Tel Aviv, Israel – May 1, 2023 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive safety results in the first part of its two-part Phase […]
